First-Year Experiences with the Interagency Guidelines for Drug Donations
(2000; 51 pages)
Table des matières
Afficher le documentAcknowledgements
Afficher le documentExecutive summary
Ouvrir ce répertoire et afficher son contenu1. Introduction
Ouvrir ce répertoire et afficher son contenu2. Sources of information and study methodology
Ouvrir ce répertoire et afficher son contenu3. Dissemination and uptake of the Guidelines
Fermer ce répertoire4. Basic characteristics of drug donations
Afficher le documentMagnitude of donations made in the past 12 months
Afficher le documentCost basis of donation value
Afficher le documentPercentage of donations made for emergencies
Afficher le documentPercentage of donations based on specific requests
Ouvrir ce répertoire et afficher son contenu5. Practical benefits as a result of the Guidelines
Afficher le document6. Drug donations which were hampered, delayed or cancelled
Ouvrir ce répertoire et afficher son contenu7. Experiences and opinions regarding the 12-month shelf-life requirement
Ouvrir ce répertoire et afficher son contenu8. Other suggestions to improve the Guidelines
Ouvrir ce répertoire et afficher son contenu9. How could donation practice be further improved?
Afficher le document10. Summary of recommendations
Afficher le document11. Postscript
Afficher le documentReferences
 

Magnitude of donations made in the past 12 months

The total value of donations reported by the donors in this study was US$ 298 million - 14 industry donors contributed US$ 228 million (76%), 11 non-governmental organizations contributed US$ 68 million (23%) and governmental agencies contributed US$ 3 million (1%). Consolidators represented in this study reported donations totalling US$ 360 million.

There were huge differences in size between amounts donated by the various donors. For example, one pharmaceutical industry donor reported annual donations of US$ 170 million, which is 74% of all industry donors. The four largest donors (with US$ 170, 18, 15 and 11 million) constitute 94% of industry donations. The situation is similar with regard to consolidators. With a reported annual turnover of US$ 148 and 141 million, the two largest consolidators constitute 80% of all consolidators.

Soft loans by the World Bank as well as the many ongoing bilateral drug donations by the Governments of Denmark, the Netherlands, Sweden and other countries are not included in this overview. The former are estimated at about US$ 300 million a year, while the latter are not really known but can be estimated at several tens of millions of dollars per government per year. These are all donations of procured drugs (usually through tender).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013